TOPLINE: Patients with rectal cancer managed by watch and wait and subsequent local regrowth have a higher risk for distant metastases than those undergoing immediate surgery. […]

TOPLINE: Fidanacogene elaparvovec gene therapy reduced the annualized bleeding rate by 71% in patients with hemophilia B. Factor IX activity levels were sustained at 26.9% at […]

TOPLINE: Trastuzumab duocarmazine (T-Duo) improved progression-free survival to 7.0 months compared with 4.9 months with a physician’s choice in advanced human epidermal growth factor receptor 2–positive […]

TOPLINE:  Combining thoracic radiotherapy with first-line EGFR tyrosine kinase inhibitor (TKI) therapy improves progression-free survival by 6.5 months and overall survival by more than 8 months […]

TOPLINE: Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient (dMMR) tumors, […]

TOPLINE: Atezolizumab combined with targeted therapy improved median overall survival to 19 months in patients with anaplastic thyroid carcinoma (ATC). The longest survival was observed in […]

TOPLINE: Stroke rates in Californians with sickle cell disease (SCD) have increased in both children and adults in the post-STOP era. The cumulative incidence of first […]

TOPLINE:  Older non-Hispanic Black adults with breast cancer are less likely to receive guideline-concordant care and timely treatment than non-Hispanic White adults, according to findings from […]